Protagonist (PTGX) hits on all key endpoints…

Mar 5

Protagonist Therapeutics (NASDAQ:PTGX) said on March 3, 2025, that its phase III Verify trial testing rusfertide in phlebotomy-dependent polycythemia vera (PV) patients met its primary endpoint and all four key secondary endpoints.

Read →

Comments

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts

Biotech Currents

Protagonist (PTGX) hits on all key endpoints…